research use only
Cat.No.S6605
| Related Targets | Dehydrogenase HSP Transferase P450 (e.g. CYP17) PDE phosphatase PPAR Vitamin Carbohydrate Metabolism Mitochondrial Metabolism |
|---|---|
| Other Retinoid Receptor Inhibitors | TTNPB AM580 Tamibarotene UVI 3003 Fenretinide SR 11237 BMS493 Palovarotene CD1530 CD3254 |
|
In vitro |
DMSO
: 4 mg/mL
(15.52 mM)
Water : Insoluble Ethanol : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 257.71 | Formula | C15H12ClNO |
Storage (From the date of receipt) | 3 years -20°C powder |
|---|---|---|---|---|---|
| CAS No. | 80306-38-3 | -- | Storage of Stock Solutions |
|
|
| Synonyms | N/A | Smiles | CC1=CC=C(C=C1)C2=NC3=C(C=C(C=C3)Cl)OC2 | ||
| In vitro |
AR7 significantly activates CMA activity in mouse fibroblasts. A marked increase in CMA-activating potency is found when this compound and GR1 are combined, supporting their cooperative effect. Treatment with the transcriptional repressor Actinomycin D partially reduces the stimulatory effect of this chemical on CMA, consistent with transcriptional changes contributing to the upregulation of CMA. |
|---|---|
| In vivo |
Reactivation of CMA by treatment with AR7 inhibits diclofenac-induced lipid accumulation and hepatotoxicity. |
References |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.